Warning: Parameter 2 to SyndicationDataQueries::posts_search() expected to be a reference, value given in /homepages/8/d142905106/htdocs/old_newsstef78/wp-includes/class-wp-hook.php on line 298

Warning: Parameter 2 to SyndicationDataQueries::posts_where() expected to be a reference, value given in /homepages/8/d142905106/htdocs/old_newsstef78/wp-includes/class-wp-hook.php on line 298

Warning: Parameter 2 to SyndicationDataQueries::posts_fields() expected to be a reference, value given in /homepages/8/d142905106/htdocs/old_newsstef78/wp-includes/class-wp-hook.php on line 298

Warning: Parameter 2 to SyndicationDataQueries::posts_request() expected to be a reference, value given in /homepages/8/d142905106/htdocs/old_newsstef78/wp-includes/class-wp-hook.php on line 298
Cancer du sein: l’UE autorise la mise sur le marché d’un traitement de Roche | Les dernières nouvelles

Cancer du sein: l’UE autorise la mise sur le marché d’un traitement de Roche


Warning: Parameter 2 to SyndicationDataQueries::posts_search() expected to be a reference, value given in /homepages/8/d142905106/htdocs/old_newsstef78/wp-includes/class-wp-hook.php on line 298

Warning: Parameter 2 to SyndicationDataQueries::posts_where() expected to be a reference, value given in /homepages/8/d142905106/htdocs/old_newsstef78/wp-includes/class-wp-hook.php on line 298

Warning: Parameter 2 to SyndicationDataQueries::posts_fields() expected to be a reference, value given in /homepages/8/d142905106/htdocs/old_newsstef78/wp-includes/class-wp-hook.php on line 298

Warning: Parameter 2 to SyndicationDataQueries::posts_request() expected to be a reference, value given in /homepages/8/d142905106/htdocs/old_newsstef78/wp-includes/class-wp-hook.php on line 298
Le groupe pharmaceutique suisse Roche a annoncé mardi que l'Union européenne avait autorisé la mise sur le marché de Perjeta, un traitement pour une forme agressive de cancer du sein.

Laisser un commentaire

Votre adresse de messagerie ne sera pas publiée. Les champs obligatoires sont indiqués avec *

© Les dernières nouvelles
CyberChimps